FMP
Dec 04, 2025
On December 3, 2025, PVH Corporation (NYSE:PVH) reported earnings per share (EPS) of $2.83, surpassing the estimated $2.56. PVH, known for its iconic brands like Calvin Klein and Tommy Hilfiger, has consistently outperformed expectations. Despite a decrease from last year's $3.03 per share, the recent EPS still represents a positive earnings surprise of 10.55%. PVH's revenue for the quarter ending October 2025 reached approximately $2.29 billion, exceeding the forecasted $2.28 billion. This marks a 1.16% increase over the Zacks Consensus Estimate and a slight rise from the $2.26 billion reported in the same period last year.
The company has consistently surpassed consensus revenue estimates over the past four quarters, showcasing its strong performance in the Textile - Apparel industry. Despite the positive earnings report, PVH's stock price experienced a decline during Wednesday's extended trading session. This was due to fourth-quarter EPS guidance falling short of analyst expectations. However, the company still reported adjusted earnings of $2.83 per share, surpassing the analyst estimate of $2.56, and achieved quarterly revenue of $2.29 billion, slightly exceeding the consensus estimate. PVH's financial metrics indicate a strong market position.
With a price-to-earnings (P/E) ratio of approximately 8.99, the market values its earnings favorably. The price-to-sales ratio of about 0.48 suggests a relatively low market valuation compared to its revenue. Additionally, the enterprise value to sales ratio is approximately 0.94, reflecting the company's total valuation in relation to its sales. The company's financial health is further supported by an enterprise value to operating cash flow ratio of around 12.56, indicating efficient cash flow management. An earnings yield of 11.13% offers a substantial return on earnings relative to the share price. PVH maintains a balanced debt-to-equity ratio of approximately 0.88 and a current ratio of 1.37, suggesting a healthy level of liquidity to cover short-term liabilities.
Pharvaris (NASDAQ:PHVS) is a biopharmaceutical company focused on developing oral treatments for hereditary angioedema (...
Nu Holdings (NYSE:NU) is a prominent digital banking platform in Latin America, offering a range of financial services. ...